Zacks Research Forecasts Lower Earnings for Zimmer Biomet

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for shares of Zimmer Biomet in a report released on Monday, January 20th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings per share of $2.01 for the quarter, down from their previous forecast of $2.02. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.46 EPS, Q1 2026 earnings at $2.25 EPS, Q2 2026 earnings at $2.33 EPS, Q4 2026 earnings at $2.32 EPS and FY2026 earnings at $9.10 EPS.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.65 EPS.

Other equities analysts have also issued research reports about the company. Raymond James lowered their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Truist Financial raised their target price on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Oppenheimer lowered their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Evercore ISI dropped their price target on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $110.54 on Wednesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet has a 1 year low of $100.67 and a 1 year high of $133.90. The stock has a market capitalization of $22.00 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.88 and a beta of 1.02. The company’s 50-day moving average is $107.84 and its 200 day moving average is $108.04.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Bancorp Inc ME grew its stake in Zimmer Biomet by 110.4% during the 4th quarter. First Bancorp Inc ME now owns 4,145 shares of the medical equipment provider’s stock valued at $442,000 after acquiring an additional 2,175 shares in the last quarter. Gradient Investments LLC boosted its position in shares of Zimmer Biomet by 5.5% during the 4th quarter. Gradient Investments LLC now owns 168,972 shares of the medical equipment provider’s stock worth $17,849,000 after purchasing an additional 8,787 shares during the period. CX Institutional grew its stake in shares of Zimmer Biomet by 171.9% in the fourth quarter. CX Institutional now owns 2,336 shares of the medical equipment provider’s stock valued at $247,000 after buying an additional 1,477 shares in the last quarter. Brighton Jones LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth about $204,000. Finally, Dakota Wealth Management lifted its holdings in Zimmer Biomet by 1.3% during the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock worth $1,016,000 after buying an additional 122 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.